Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug
作者： Paul A Marks , Ronald Breslow
DOI: 10.1038/NBT1272
关键词:
摘要: … is a histone deacetylase inhibitor. SAHA reacts with and blocks the catalytic site of these … and RB) met to discuss the question of how to discover the basis of the DMSO effects. This …
nature.com
sci-hub.se 参考文章(49)
Michael Sheffery, Richard A. Rifkind, Paul A. Marks, Induction of Transformed Cells to Terminal Differentiation and the Modulation of Gene Expression Cancer Research. ,vol. 47, pp. 659- 666 ,(1987)
Owen A. O'Connor, Mark L. Heaney, Lawrence Schwartz, Stacie Richardson, Robert Willim, Barbara MacGregor-Cortelli, Tracey Curly, Craig Moskowitz, Carol Portlock, Steven Horwitz, Andrew D. Zelenetz, Stanley Frankel, Victoria Richon, Paul Marks, William K. Kelly, Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies Journal of Clinical Oncology. ,vol. 24, pp. 166- 173 ,(2006) , 10.1200/JCO.2005.01.9679
Lisa M Butler, David B Agus, Howard I Scher, Brian Higgins, Adam Rose, Carlos Cordon-Cardo, Howard T Thaler, Richard A Rifkind, Paul A Marks, Victoria M Richon, None, Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Research. ,vol. 60, pp. 5165- 5170 ,(2000)
William Kevin Kelly, Owen A. O'Connor, Lee M. Krug, Judy H. Chiao, Mark Heaney, Tracy Curley, Barbara MacGregore-Cortelli, William Tong, J. Paul Secrist, Lawrence Schwartz, Stacy Richardson, Elaina Chu, Semra Olgac, Paul A. Marks, Howard Scher, Victoria M. Richon, Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer Journal of Clinical Oncology. ,vol. 23, pp. 3923- 3931 ,(2005) , 10.1200/JCO.2005.14.167
Michael S. Finnin, Jill R. Donigian, Alona Cohen, Victoria M. Richon, Richard A. Rifkind, Paul A. Marks, Ronald Breslow, Nikola P. Pavletich, Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature. ,vol. 401, pp. 188- 193 ,(1999) , 10.1038/43710
Yun Dai, Jorge A Almenara, Roberto R Rosato, Steven Grant, Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Molecular Cancer Therapeutics. ,vol. 2, pp. 1273- 1284 ,(2003)
Ricky W Johnstone, Jonathan D Licht, Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell. ,vol. 4, pp. 13- 18 ,(2003) , 10.1016/S1535-6108(03)00165-X
L. M. Butler, X. Zhou, W.-S. Xu, H. I. Scher, R. A. Rifkind, P. A. Marks, V. M. Richon, The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin Proceedings of the National Academy of Sciences of the United States of America. ,vol. 99, pp. 11700- 11705 ,(2002) , 10.1073/PNAS.182372299
Kapil N. Bhalla, Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies Journal of Clinical Oncology. ,vol. 23, pp. 3971- 3993 ,(2005) , 10.1200/JCO.2005.16.600
C. S. Mitsiades, N. S. Mitsiades, C. J. McMullan, V. Poulaki, R. Shringarpure, T. Hideshima, M. Akiyama, D. Chauhan, N. Munshi, X. Gu, C. Bailey, M. Joseph, T. A. Libermann, V. M. Richon, P. A. Marks, K. C. Anderson, Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications Proceedings of the National Academy of Sciences of the United States of America. ,vol. 101, pp. 540- 545 ,(2004) , 10.1073/PNAS.2536759100